Total Payments
$6,424
2022 Payments
$483.07
Companies
33
Transactions
456
Medicare Patients
1,540
Medicare Billing
$455,246
Payment Breakdown by Category
Food & Beverage$6,371 (99.2%)
Education$52.61 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,371 | 453 | 99.2% |
| Education | $52.61 | 3 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,146 | 85 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $926.56 | 75 | $0 (2022) |
| Janssen Biotech, Inc. | $667.68 | 48 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $596.46 | 39 | $0 (2022) |
| Ironwood Pharmaceuticals, Inc | $334.44 | 23 | $0 (2022) |
| Ferring Pharmaceuticals Inc. | $262.31 | 19 | $0 (2021) |
| Gilead Sciences, Inc. | $261.91 | 20 | $0 (2022) |
| Daiichi Sankyo Inc. | $253.71 | 19 | $0 (2021) |
| PFIZER INC. | $230.34 | 15 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $224.34 | 9 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $483.07 | 35 | ABBVIE INC. ($202.23) |
| 2021 | $1,520 | 109 | Takeda Pharmaceuticals U.S.A., Inc. ($259.57) |
| 2020 | $939.68 | 72 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($357.03) |
| 2019 | $1,123 | 84 | Takeda Pharmaceuticals U.S.A., Inc. ($175.76) |
| 2018 | $905.02 | 65 | AbbVie, Inc. ($160.55) |
| 2017 | $1,453 | 91 | AbbVie, Inc. ($355.53) |
All Payment Transactions
456 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/14/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Gastroenterology | ||||||
| 05/20/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: IMMUNOLOGY | ||||||
| 05/19/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: VIROLOGY | ||||||
| 05/18/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/10/2022 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $15.53 | General |
| Category: GI | ||||||
| 05/04/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: Immunology | ||||||
| 05/03/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.99 | General |
| 04/28/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Immunology | ||||||
| 04/19/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: VIROLOGY | ||||||
| 04/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/05/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Immunology | ||||||
| 03/31/2022 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 03/31/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Immunology | ||||||
| 03/23/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: VIROLOGY | ||||||
| 03/21/2022 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $14.30 | General |
| Category: GI | ||||||
| 03/17/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: IMMUNOLOGY | ||||||
| 03/16/2022 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/10/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Immunology | ||||||
| 02/22/2022 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/16/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: IMMUNOLOGY | ||||||
| 02/10/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/09/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: VIROLOGY | ||||||
| 02/09/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: Gastroenterology | ||||||
| 02/08/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 7 | 314 | 8,145 | $521,285 | $159,856 |
| 2021 | 12 | 665 | 9,882 | $836,853 | $228,626 |
| 2020 | 9 | 561 | 820 | $230,847 | $66,765 |
Total Patients
1,540
Total Services
18,847
Medicare Billing
$455,246
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 13 | 7,800 | $397,800 | $132,972 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 196 | 223 | $44,600 | $13,933 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 33 | $14,751 | $3,140 | 21.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 14 | 14 | $20,160 | $2,943 | 14.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $7,455 | $2,661 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 31 | $8,804 | $2,336 | 26.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $27,715 | $1,869 | 6.7% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2021 | 13 | 9,000 | $459,000 | $141,320 | 30.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 298 | 492 | $97,269 | $35,639 | 36.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 100 | $28,400 | $11,314 | 39.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 66 | 66 | $23,430 | $9,203 | 39.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 75 | 75 | $89,630 | $7,392 | 8.2% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 27 | 27 | $38,880 | $6,017 | 15.5% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 21 | 42 | $18,774 | $5,173 | 27.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 24 | 24 | $33,240 | $3,747 | 11.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 15 | 15 | $16,050 | $3,054 | 19.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 14 | 14 | $14,980 | $2,855 | 19.1% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 13 | 13 | $13,910 | $1,955 | 14.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $3,290 | $956.44 | 29.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 325 | 569 | $61,029 | $32,978 | 54.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 68 | 68 | $14,450 | $8,980 | 62.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 66 | 68 | $58,855 | $6,342 | 10.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 23 | 23 | $27,000 | $4,416 | 16.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 21 | 21 | $19,170 | $4,336 | 22.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 13 | 26 | $6,738 | $3,357 | 49.8% |
About Dr. M Arif Hashmi, M.D
Dr. M Arif Hashmi, M.D is a Specialist healthcare provider based in Haddon Heights, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497743975.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. M Arif Hashmi, M.D has received a total of $6,424 in payments from pharmaceutical and medical device companies, with $483.07 received in 2022. These payments were reported across 456 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($6,371).
As a Medicare-enrolled provider, Hashmi has provided services to 1,540 Medicare beneficiaries, totaling 18,847 services with total Medicare billing of $455,246. Data is available for 3 years (2020–2022), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Gastroenterology
- Location Haddon Heights, NJ
- Active Since 10/10/2005
- Last Updated 05/13/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1497743975
Products in Payments
- XIFAXAN (Drug) $816.43
- STELARA (Biological) $667.68
- Humira (Biological) $321.26
- Linzess (Drug) $257.46
- INJECTAFER (Drug) $205.31
- ENTYVIO (Biological) $198.60
- Entyvio (Biological) $198.44
- LINZESS (Drug) $193.72
- Cimzia (Drug) $187.47
- VIBERZI (Drug) $187.08
- HUMIRA (Biological) $186.93
- XIFIXAN (Drug) $180.51
- CLENPIQ (Drug) $166.15
- Mavyret (Drug) $164.18
- XELJANZ (Drug) $159.66
- Sucraid (Drug) $139.17
- ZEPOSIA (Drug) $136.47
- Amitiza (Drug) $130.50
- MOTEGRITY (Drug) $128.12
- RENFLEXIS (Biological) $115.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Haddon Heights
John Kolnik, D.o, D.O
Specialist — Payments: $158,544
Specialist $158,544
James Izanec, Md, MD
Specialist — Payments: $14,506
Specialist $14,506
Jay Malamut, M.d, M.D
Specialist — Payments: $6,548
Specialist $6,548
Dr. Denise Mastromonaco, D.o, D.O
Specialist — Payments: $2,690
Specialist $2,690
Boris Libster, D.o, D.O
Specialist — Payments: $1,410
Specialist $1,410
Howard Siegel, M.d, M.D
Specialist — Payments: $1,353
Specialist $1,353